Department of Medicine
Benjamin Derman is an expert in multiple myeloma and other plasma cell disorders, such as monoclonal gammopathy, amyloidosis, plasmacytoma, and POEMS syndrome. He diagnoses and treats cancerous conditions and uses innovative techniques, including CAR T-cell therapy and stem cell transplantation, to deliver long-term success for his patients. His research focuses on identifying strategies that can lead to a cure for multiple myeloma, including using tests that measure small amounts of residual cancer cells in the body called minimal residual disease to guide decision making. He is also investigating new methods and therapies to improve outcomes and quality of life for his patients. Additionally, he is interested in evaluating reasons for racial disparities in multiple myeloma outcomes, to better understand and care for those patients.
His work has been published in the Journal for ImmunoTherapy of Cancer, Blood, Blood Advances, Blood Cancer Journal, Leukemia & Lymphoma, and the British Journal of Haematology. He is a member of the American Society for Blood and Marrow Transplantation, the American Society of Clinical Oncology, and the American Society of Hematology, and has board certifications in oncology, hematology, and internal medicine.
Derman received his MD from Northwestern University’s Feinberg School of Medicine. He completed his internal medicine residency at Rush University Medical Center and a fellowship in hematology and oncology at the University of Chicago.